DOI: https://doi.org/10.36347/sasjm.2026.v12i04.010

Pages: 289-292

Purpose: To evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation in the management of refractory glaucoma. Methods: This retrospective case series included 15 eyes from 15 patients with refractory glaucoma treated between January 2024 and March 2025 at the Ophthalmology Department of the Avicenna Military Hospital of Marrakech. The primary outcome was intraocular pressure (IOP) reduction, while secondary outcomes included changes in the number of antiglaucoma medications and postoperative complications. Treatment success was defined as an IOP ≤ 20 mmHg without intensification of medical therapy. Results: The mean preoperative IOP was 32.5 ± 5.7 mmHg. Following treatment, mean IOP decreased to 25.2 ± 7.5 mmHg at day 1, 20.9 ± 5.0 mmHg at day 7, and 22.6 ± 7.3 mmHg at day 30. At 6 weeks, mean IOP reached 16.6 ± 5.1 mmHg, corresponding to a 56.5% reduction from baseline (p < 0.001). The mean number of antiglaucoma medications decreased from 3.2 ± 1.3 preoperatively to 1.6 ± 0.9 at 6 weeks, representing a 51.1% reduction (p < 0.001). At 3 months, 12 patients were available for follow-up, of whom 10 maintained satisfactory IOP control with 1–2 medications, while one patient required repeat treatment. Conclusion: Transscleral diode laser cyclophotocoagulation appears to be an effective and relatively safe option for the management of refractory glaucoma, providing significant IOP reduction and decreasing treatment burden. Further studies with larger cohorts and longer follow-up are warranted to confirm these findings.